Voters pass end-of-life measure in Washington state

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Washington state voters passed an initiative that allows doctors to prescribe lethal prescriptions to terminally ill patients who have six months or less to live.

Washington state voters passed an initiative that allows doctors to prescribe lethal prescriptions to terminally ill patients who have six months or less to live. Under Initiative 1000, patients must request the prescription from the physician and must self-administer the lethal medication. The measure also states that two physicians have to determine that the patient has an incurable disease that will cause death within six months. The physician must also recommend, but not require, the patient to notify next of kin.

The initiative is similar to Oregon’s Death With Dignity Act, which took eff ect in 1998. I-1000 marks the second time Washington voters decided an end-of-life measure. In 1991 residents rejected Initiative 119, which would have allowed doctors to write and administer lethal prescriptions, unlike I-1000 which only permits the prescription. Where do you stand on this issue? See page 2 and visit www.cancernetwork.com to register your vote to the question, “Do you agree with physician-assisted suicide?”

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content